Wuhan Hiteck Biological Pharma: China Investment Securities Co., Ltd.'s regular on-site inspection report on the company's continuous supervision work for the second half of 2023

SZSI · May 7

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.